Los Angeles, CA (PRWEB) December 06, 2013
Over the five years to 2013, the Global Pharmaceuticals and Medicine Manufacturing industry enjoyed steady growth, despite a number of changes to the industry's landscape. Industry revenue grew as a result of increased access to more comprehensive healthcare in developing countries and demographic shifts necessitating more healthcare expenditure. “The increasing number of global middle-class individuals has also translated into dramatic increases in demand for pharmaceuticals,” according to IBISWorld Industry Analyst Anna Son. Industry growth has been restrained, however, by the potent combination of a historically high level of patent expirations on blockbuster drugs, accelerating competition from generics and contributing to a depleted product pipeline, with fewer new medicines being marketed. Growing price pressures from governments and health insurance organizations around the globe has also placed significant strain on the industry.
During the five years to 2013, IBISWorld estimates that industry revenue will grow at an average annual rate of 3.7% to total $1.1 trillion. Over this year, the industry will continue to be challenged by key patent expirations and continued pricing pressures, amid changing healthcare access and funding issues. At the same time, emerging markets such as China, India and Brazil, will continue driving sales of pharmaceuticals. “Development in these markets is significantly exceeding the growth rates of more mature markets, such as the United States and Western Europe, which have to contend with increased regulation and significant changes in healthcare policy, due to various austerity measures and healthcare reforms,” says Son. However, despite these obstacles, revenue is forecast to grow 3.4% in 2013 overall.
In the short term, the industry is expected to continue its gradual transformation process. That is to say, emerging markets will continue to grow in importance as the geographic base of the industry gradually moves away from the traditional market powerhouses. Meanwhile, diversification strategies and merger and acquisition activity will remain key features that will characterize the industry's evolution. In addition, large-cap pharmaceutical companies will seek to acquire or partner with biotechnology companies with promising drug candidates, in order to bolster thinning pipelines.
For more information, visit IBISWorld’s Global Pharmaceuticals & Medicine Manufacturing industry report page.
Follow IBISWorld on Twitter: https://twitter.com/#!/IBISWorld
Friend IBISWorld on Facebook: http://www.facebook.com/pages/IBISWorld/121347533189
IBISWorld industry Report Key Topics
This industry comprises companies that manufacture biological, medicinal and pharmaceutical products in various forms including ampoules, tablets, capsules, vials, ointments, powders, solutions and suspensions. The overall pharmaceutical market can be segmented into prescription-based (or ethical) products and over-the-counter medications. Industry products are predominantly distributed via wholesalers, and are then sold via pharmacies or distributed in hospitals.
Key External Drivers
Industry Life Cycle
Products & Markets
Products & Services
Globalization & Trade
Market Share Concentration
Key Success Factors
Cost Structure Benchmarks
Barriers to Entry
About IBISWorld Inc.
Recognized as the nation’s most trusted independent source of industry and market research, IBISWorld offers a comprehensive database of unique information and analysis on nearly every US and Global industry. With an extensive online portfolio, valued for its depth and scope, the company equips clients with the insight necessary to make better business decisions. Headquartered in Los Angeles, IBISWorld serves a range of business, professional service and government organizations through more than 10 locations worldwide. For more information, visit http://www.ibisworld.com or call 1-800-330-3772.
Read the full story at http://www.prweb.com/releases/2013/12/prweb11396790.htm.
Copyright©2012 Vocus, Inc.
All rights reserved